Related Experiment Video
Updated: Feb 6, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Antitumor effects of anlotinib in thyroid cancer
Xianhui Ruan1, Xianle Shi2, Qiman Dong2
1Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Abstract:
There is no effective treatment for patients with poorly differentiated papillary thyroid cancer or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. In this study, we aimed to better understand the effect and efficacy of anlotinib against thyroid carcinoma cells in vitro and in vivo. We found that anlotinib inhibits the cell viability of papillary thyroid cancer and ATC cell lines, likely due to abnormal spindle assembly, G2/M arrest, and activation of TP53 upon anlotinib treatment. Moreover, anlotinib suppresses the migration of thyroid cancer cells in vitro and the growth of xenograft thyroid tumors in mice. Our data demonstrate that anlotinib has significant anticancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type.
Insights
Anlotinib, a multi-kinase inhibitor, effectively combats poorly differentiated papillary thyroid cancer and anaplastic thyroid cancer (ATC) by inhibiting cell viability and tumor growth. This study suggests anlotinib as a promising therapeutic strategy for advanced thyroid cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anaplastic thyroid cancer (ATC) and poorly differentiated papillary thyroid cancer lack effective treatments.
- Anlotinib, a multi-kinase inhibitor, has demonstrated antitumor activity in other cancers.
Purpose of the Study:
- To investigate the in vitro and in vivo efficacy of anlotinib against thyroid carcinoma cells.
- To explore the molecular mechanisms underlying anlotinib's anti-cancer effects in thyroid cancer.
Main Methods:
- In vitro studies using papillary thyroid cancer and ATC cell lines.
- In vivo studies involving xenograft mouse models.
- Analysis of cell viability, migration, cell cycle, and protein expression.
Main Results:
- Anlotinib significantly inhibited thyroid cancer cell viability and migration in vitro.
- Anlotinib treatment led to abnormal spindle assembly, G2/M cell cycle arrest, and TP53 activation.
- Anlotinib suppressed the growth of thyroid cancer xenograft tumors in mice.
Conclusions:
- Anlotinib exhibits significant anticancer activity against papillary thyroid cancer and ATC.
- Anlotinib demonstrates potential as a novel therapeutic strategy for advanced thyroid cancer.
Related Concept Videos
The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects
Biological Effects of Radiation

